ALTERATIONS IN TRETINOIN PHARMACOKINETICS FOLLOWING ADMINISTRATION OFLIPOSOMAL ALL-TRANS-RETINOIC ACID

We administered liposome-encapsulated all-trans retinoic acid (L-ATRA) to 48 patients with refractory hematologic malignancies using an ever y-other-day schedule for 28 days and doses of 15 to 175 mg/m(2). In 19 patients, pharmacology studies were conducted after the first (day 1) and seventh (day 15) doses, In contrast to the decline in tretinoin c oncentration seen within 3 to 4 days of administration of daily oral A TRA, there were no differences between the area under the curve (AUG) of tretinoin concentration versus time on day 1 and day 15 (P = .98, W ilcoxon signed-rank test). Peak day 1 concentrations after 15 mg/m(2) were higher than those reported after 45 mg/m(2) oral ATRA. Six patien ts with relapsed acute promyelocytic leukemia (APL) were treated. Thre e, each in first relapse and at least year from the last exposure to o ral ATRA, achieved a complete response (CR). Disease recurred in two ( one at 3 months despite maintenance L-ATRA and similarity in tretinoin AUC on days 1 and 85, and the other at 5 months, 2 months after disco ntinuation of L-ATRA) and the third was transplanted 1 month into CR, The three nonresponders were in at least a second relapse and failed t o respond to oral ATRA before or immediately after receiving L-ATRA. S evere toxicity developed in three of eight patients treated at 175 mg/ m(2) (joint pains in two, skin in one). The maximum tolerated dose (MT D) was determined to be 140 mg/m(2), at which dose grade 2 toxicity (p rimarily headache and skin) occurred in eight of eight patients, but g rade 3 to 4 toxicity in none, Compared with oral ATRA, L-ATRA apparent ly results in greater exposure to tretinoin and for a longer time. (C) 1996 by The American Society of Hematology.